Long wait times for elective services are seen as one of the major challenges for Canadian healthcare. Canadians report that they wait longer for specialists than citizens in other countries. The main reason for this is that the referral process is poorly coordinated and leads to delays in care. Electronic referral (eReferral) is seen as a potential means of improving the referral process and enabling faster access to care. There is the potential for national implementation of eReferral in Canada to help achieve this aim. However, existing initiatives have encountered challenges with user adoption and users have continued to use fax. A validated tool was used to survey both users of fax as well as users of eReferral. These two groups of users were then compared. Most family physicians using fax were satisfied overall with the process. This highlighted how challenging any change of this engrained technology will be. There were, however, some significant areas were eReferral was superior to fax. This included response time, the overall quality of referral information, completeness of the information, the timeliness of the information, and the format and layout. There is an opportunity to leverage these findings to support the adoption of eReferral and help reduce wait times.
Download full-text PDF |
Source |
---|
Int J Pediatr Otorhinolaryngol
December 2024
Hacettepe University, Faculty of Medicine, Department of Opthalmology, Ankara, Turkey.
Aims And Objectives: This study aimed to investigate the presence, type, and severity of hearing losses in individuals with Duane Retraction Syndrome (DRS), and to ascertain if there are anomalies in the auditory pathways at the brainstem level in DRS, believed to arise from aberrant interaction between cranial nerves and brainstem nuclei.
Study Design: Cross-sectional observational study.
Setting: Tertiary referral centre.
Semergen
December 2024
Departamento de Educação Integrada em Saúde, Universidade Federal do Espírito Santo, Vitória, ES, Brazil. Electronic address:
Objectives: This study aimed to develop a mobile application (App) to be used by primary care teams in the active search for functional impairment, long-term symptoms, and disabilities in individuals who have recovered from COVID-19, contributing to early treatment and referrals for multidisciplinary care and rehabilitation. This experimental study used the minimum viable product (MVP) methodology to develop an App named ReabilitaCOVID.
Methods: This methodology involves ideation, content creation, prototype creation, usability tests, and adjustments based on feedback.
Aten Primaria
December 2024
Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla, España; Departamento de Medicina, Universidad de Sevilla, Sevilla, España.
Objective: To analyze the reliability and validity of the SERVPERF questionnaire for assessing the quality of care from the patient's perspective in emergency departments for abdominal pain patients undergoing clinical ultrasound, as well as the influence of sex.
Design: Prospective study from March 2023 to April 2024 involving patients treated for abdominal pain who underwent clinical ultrasound.
Setting: Emergency department.
Am J Otolaryngol
December 2024
Dr. Elie E. Rebeiz Department of Otolaryngology - Head and Neck Surgery, Tufts Medical Center, Boston, MA, USA. Electronic address:
Objective: This retrospective cohort study aims to compare donor site morbidity of three commonly used upper extremity flaps used in head and neck reconstructive surgery: scapular tip free flap (STFF), radial forearm free flap (RFFF), and pectoralis major pedicled flap (PMPF).
Methods: The billing database of an urban, academic, tertiary otolaryngology practice was queried to identify patients who underwent STFF, RFFF, and PMPF from 2020 to 2023. The primary outcome was identification of donor site pain and need for physical therapy (PT) referral after undergoing reconstruction.
Actas Dermosifiliogr
December 2024
Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB), Spain.
Introduction: Clinical trials have validated the use of nivolumab and pembrolizumab as adjuvant therapies regarding relapse-free survival (RFS) in patients with resected stage III and IV melanoma. Evidence in real-world patients is currently limited.
Material And Method: The CADIM trial (Characterization of adjuvant immunotherapy in melanoma patients) recruited a total of 81 patients with resected stage III and IV melanoma on nivolumab or pembrolizumab as adjuvant therapy from February 2018 through December 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!